Turn £10k Into £30k With AstraZeneca plc

AstraZeneca plc (LON: AZN) would have trebled your money in 10 years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaIf you’d held AstraZeneca (LSE: AZN) (NYSE: AZN.US) shares over the past 12 months, you’d have done pretty nicely with a 40% rise to 4,544p.

A lot of that is down to the Pfizer bid, mind, but the turnaround plan put in place by new boss Pascal Soriot was already boosting the shares. And over three years you’d be sitting on a gain of more than 60%.

But Fools are in it for the long term, so what would an investment in AstraZeneca a full 10 years ago be worth now?

Double your money

In September 2004, AstraZeneca shares were changing hands for around 2,265p, so if you’d invested £10,000 at the time you would have picked up 442 shares. Wind forward to today, and with AstraZeneca shares priced at 4,544p you’d have enjoyed a 101% capital gain — you’d have more than doubled your £10,000 in 10 years to £20,062.

Bear in mind that the period covered two traumatic events for AstraZeneca. One was the recession that hit the entire FTSE, but we also had the so-called patent cliff that saw the end of protection of some key drugs. Between late 2006 and early 2008, AstraZeneca shares lost a massive 49%, and investors could be forgiven for not being too impressed by the stock market at the time.

But even if you’d bought in at the very peak of 2006 and suffered the crunch, your shares would still be worth 30% more today! As failures go, I’ve seen worse.

Don’t forget the dividends

If that 10-year doubling impressed you, don’t forget there’s more to come in the shape of dividends. Early in the decade, AstraZeneca was handing out yields of between 2% and 3%, which was a little below the FTSE 100 average. But the dividend was on the rise, and by 2009 it was yielding 5% — and it got as high as 6.1% in 2011.

Altogether, the annual cash handout would have netted you an additional £5,617, giving you a total of £25,679 for an overall return of 157%.

But we don’t want to give you that!

Buy more shares!

No, if you hadn’t needed to spend your dividends, you’d have built an even bigger pot had you reinvested the cash in more AstraZeneca shares every year.

Just those few extra few shares every year would have added another £4,471 to your investment! That’s an extra 45% return on your original £10,000.

Your total gain with all dividends reinvested over 10 years? A pretty cool £30,150! And you’d be starting the next decade with 639 shares instead of your original 442.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A senior man using hiking poles, on a hike on a coastal path along the coastline of Cornwall. He is looking away from the camera at the view.
Investing Articles

Is Diageo quietly turning into a top dividend share like British American Tobacco?

Smoking may be dying out but British American Tobacco remains a top dividend share. Harvey Jones wonders if ailing spirits…

Read more »

Young woman holding up three fingers
Investing Articles

Just released: our 3 top income-focused stocks to consider buying in December [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Tesco’s share price: is boring brilliant?

Tesco delivers steady profits, dividends, and market share gains. So is its share price undervaluing the resilience of Britain’s biggest…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

1 huge takeaway from the Martin Lewis investing presentation

Martin Lewis showed how returns from stocks have smashed the returns from cash savings over the last decade. But here’s…

Read more »

Middle aged businesswoman using laptop while working from home
Investing For Beginners

I think the best days for Lloyds’ share price are over. Here’s why

Jon Smith explains why Lloyds' share price could come under increasing pressure over the coming year, with factors including a…

Read more »

A graph made of neon tubes in a room
Investing Articles

£5,000 invested in the FTSE 100 at the start of 2025 is now worth…

Looking to invest in the FTSE 100? Royston Wild believes buying individual shares could be the best way to target…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Can the BAE share price do it again in 2026?

The BAE share price has been in good form in 2025. But Paul Summers says a high valuation might be…

Read more »

Investing Articles

Can Rolls-Royce, Babcock, and BAE Systems shares do it all over again in 2026?

Harvey Jones examines whether BAE Systems and other defence-focused FTSE 100 stocks can continue to shoot the lights out in…

Read more »